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Abstract
Background: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is
clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice
across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment
response, and post-treatment surgical management.
Methods: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A
detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017
and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item.
Results: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant
chemotherapy (NACT) to a median of 10% (range 5–60%) of patients. Neoadjuvant endocrine therapy (NET) was
offered to a median of 4% (range 0–25%) of patients by 66% of MDTs. The principal indication given for use of
neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring
of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-
five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response.
Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB)
in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would
receive axillary node clearance at 60% of centres, regardless of response to NACT.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: s.mcintosh@qub.ac.uk
21Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast,
97 Lisburn Road, Belfast BT9 7AE, UK
Full list of author information is available at the end of the article
Whitehead et al. BMC Cancer           (2021) 21:90 
https://doi.org/10.1186/s12885-020-07757-6
(Continued from previous page)
Discussion: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general
low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all
centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed
multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be
corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and
clinical outcomes.
Keywords: Breast cancer, Neoadjuvant treatment, Chemotherapy, Endocrine therapy, Surgery
Background
Breast cancer affects around 55,000 women per year in
the United Kingdom, and over recent years breast cancer
management has evolved, with increasing use of perso-
nalised approaches to therapy. This includes the use of
neoadjuvant systemic therapy (NST), which may be used
to reduce the extent of surgery, as well as to determine
the sensitivity of a tumour to therapy in the in vivo set-
ting. Long-term results from randomised control trials
comparing neoadjuvant with adjuvant chemotherapy
(NACT) have demonstrated no significant difference in
distant recurrence, breast cancer mortality or any cause
mortality [1]. Furthermore, pathological response to neo-
adjuvant chemotherapy has been validated as predictive of
long-term outcomes, and meta-analysis has shown that
approximately ~ 26% of unselected patients can achieve a
pathological complete response (pCR) [2, 3]. Pathological
complete response (pCR) is higher in some disease sub-
types, with for example HER2-positive breast cancers
achieving pCR rates of up to 60% [4], with much lower re-
sponse rates reported in ER-positive disease [2]. The pres-
ence of residual disease following neoadjuvant therapy
may inform the choice of subsequent adjuvant therapies,
with consequent improved outcomes [5, 6]. Furthermore,
national guidance recommends offering primary systemic
therapy to ER negative and HER2 positive invasive breast
cancer, with international guidance recommending this
approach for the treatment of stage 2 or 3 HER2 positive
or triple negative disease [7, 8].
Primary endocrine therapy has long been used in the
management of hormone receptor positive patients
deemed unfit for surgery, although the role of neoadju-
vant endocrine therapy (NET) is still being established.
Some studies have demonstrated it to be as effective as
chemotherapy in strongly hormone receptor positive dis-
ease, and the Pre-operative Endocrine Prognostic Index
has been reported as a tool for use following NET to
identify patients at risk of relapse [9]. The majority of
trials in this setting are low powered with small sample
sizes and variable treatment duration, and the extent of
NET use within UK centres remains unclear [10–12].
In both Europe and the United States, significant re-
gional variation has been reported in the use of
neoadjuvant chemotherapy [13, 14]. Similar variation
has been demonstrated in the UK, in the national Mast-
ectomy Decisions Audit (MasDA) [15]. This national
prospective study showed that many centres opted for
mastectomy over NST in almost 30% of patients with
large tumour to breast size ratio, missing potential op-
portunities for surgical downstaging. Indeed, in HER2
positive disease some 60% of patients potentially eligible
for neoadjuvant therapy proceeded directly to mastec-
tomy without such treatment in this study.
Furthermore, it has been shown that even where im-
proved pCR rates can be achieved this does not neces-
sarily impact on rates of breast conserving surgery [16].
This may be due to differences in the surgical approach
to the breast following neoadjuvant therapy, with some
surgeons resecting the original tumour footprint irre-
spective of response to treatment, whilst others will
tailor their resection to residual disease. Timing of axil-
lary staging and surgical approach to patients presenting
with node-positive disease is also controversial [17]. Fi-
nally, there is little consensus in the imaging modalities
used to monitor treatment response in the neoadjuvant
setting, nor in pathology reporting frameworks across
the UK.
This study aimed to describe the current stated practice
of multidisciplinary teams (MDTs) across the UK with re-
spect to the use of neoadjuvant systemic therapy, includ-
ing indications for use, response monitoring, pathological
reporting and surgical approaches to the breast and axilla.
It forms the first stage of the Neoadjuvant Systemic Ther-
apy in Breast Cancer (NeST) Study, a national multicen-
tre, multidisciplinary collaborative prospective study
assessing usage and real-world outcomes [18].
Methods
All surgical and oncological units treating breast cancer
within the UK were eligible to participate in the NeST
study. As with previous National Practice Questionnaires
in the UK, multidisciplinary units were invited to partici-
pate by email in December 2017 via a number of profes-
sional and research organisations [19]. These included
the Mammary Fold (MF) Breast Trainees’ Association,
the Association of Breast Surgery, the Association of
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Surgeons in Training, the National Trainee Research
Collaborative (NTRC), the Breast Cancer Trainees Re-
search Collaborative Group, the NCRI Breast Clinical
Studies Group (CSG) and the Reconstructive Surgery
Trials Network (RSTN). Thus each unit received an invi-
tation to participate through several sources during De-
cember 2017, with a further reminder invitation through
these routes sent in January 2018. No information was
collected on units which did not respond to the
invitations.
Members of the NeST steering committee developed
the national practice questionnaire (NPQ), which was
piloted in 4 centres and iteratively modified according to
feedback, to ensure ease of use. The final 68 item ques-
tionnaire collected data on multidisciplinary team
(MDT) demographics, indications for NST, proportion
of patients offered NST, preferred treatment regimes,
methods of monitoring response, subsequent surgical
management and reporting of pathological response.
The questionnaire was issued to all MDTs participating
in the NeST study via the secure electronic database,
REDCap in December 2017 [20], and is provided as Sup-
plementary Data. Respondents were asked to complete
the questionnaire at their weekly multidisciplinary meet-
ings, where all specialties were present. Data was
uploaded to REDCap by the local lead for the NeST
study. MDTs with incomplete NPQs were contacted via
e-mail and invited to input missing data in order to
maximise data capture, which was completed by Sep-
tember 2019.
All participating institutions gained local governance
approval for participation in the study.
Simple summary statistics were calculated for each
questionnaire item. Categorical data were summarised
by counts and percentages. Continuous data was sum-
marised by mean, median, standard deviation and ranges
as appropriate. Statistical tests were carried out using
Graphpad Prism 9.
Results
Responses were obtained from a total of 39 of 144 UK
MDTs. Characteristics of participating centres’ service
provision and MDT composition are summarised in
Table 1.
Indications and selection for Neoadjuvant therapy
All MDTs in the study reported routinely offering
NACT to their patients, with an estimated median of
10% (range 5–60%) cases being offered this modality.
The median usage of NACT in teaching hospitals was
10% (range 5–40%), as compared with 7.75% in DGHs
(range 5–60%) (p=0.32, Mann-Whitney U test).
Twenty–six MDTs (66% of the total) routinely offered
NET; a further 5% (n=2) offer NET only as a treatment
option within a clinical trial. For teaching hospitals, 22%
did not routinely offer NET, whereas for DGHs this fig-
ure was 27%. A median of 4% (range 0–25%) of patients
were offered NET at these centres, with a median dur-
ation of treatment of 6 months (range: 3–9 months). At
teaching hospitals, the median number of patients of-
fered NET was 5% (range 0.2–25%), and at DGHs the
corresponding figures were 2.5% (range 0.5–12.5%) (p=
0.41, Mann-Whitney U test).
Indications for recommending neoadjuvant therapy
are summarised in Fig. 1. The most common indication
of the use of both NACT and NET was for the downsta-
ging of disease, either to treat locally advanced disease
or to downstage planned surgery.
Neoadjuvant chemotherapy regimens most commonly
reported being used are summarised in Fig. 2, with the
most commonly prescribed regimen being FEC-
docetaxel/trastuzumab/pertuzumab for HER2-positive
disease and FEC-docetaxel for HER2-negative disease.
Preferred regimens were not stated in the responses
from 6 MDTs (15%).
Neoadjuvant radiotherapy use in the UK is low, with
58% of respondents reporting that they do not use this
approach, and a further 38% stating that they would only
use it in the context of advanced or inoperable disease
unresponsive to systemic therapies and one unit only
using it in the context of a clinical trial (3%). One unit
did not respond to this question.
Table 1 Demographics of participating breast units and
multidisciplinary teams
Organisation Number (%)
Teaching Hospital 23 (59)
DGH 15 (38)
Not stated 1 (3)
Service Provision
Symptomatic only 3 (8)
Screening/symptomatic 36 (92)
Actively recruiting to trials
100 (39)
Unit size Median cases per year (range)
470 (220–1000)




Clinical oncologist 2 (0–5)
Medical oncologist 2 (0–5)
Breast Surgeons 3 (0.5–10)
Oncoplastic Breast Surgeon 3 (0.5–10)
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Fig. 1 Histogram depicting stated indications for use of neoadjuvant chemotherapy and endocrine therapy. If selecting “Other” then respondents
were invited to provide a free text response. Other responses were “downstaging of heavy nodal disease”, “HER2+ve disease ≥2 cm in diameter”,
and “to allow patients time to prepare psychologically for mastectomy/reconstruction”
Fig. 2 Most commonly prescribed neoadjuvant chemotherapy regimes according to disease subtype. a HER2 positive cancer b Triple negative
breast cancer (TNBC) c Hormone receptor positive, HER2 negative
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Monitoring and management of treatment response
Monitoring of response information was provided for all
MDTs. A marker clip is routinely sited in the breast by
97% of multidisciplinary teams when using NACT. In
79% of units this is prior to commencing treatment, with
21% varying the timing due to practicalities.
Preferred modalities for monitoring response to treat-
ment are detailed in Fig. 3 (a) and (b) for neoadjuvant
chemotherapy and endocrine therapy respectively, with
clinical assessment and/or ultrasound being utilised
most often. Response is assessed at varying time points
during treatment as follows:
 45% mid-point and end of treatment
 5% mid-point, end and other time point
 3% mid-point and other time point
 18% mid-point only
 8% end of treatment only
 18% other time point only
 3% - varies with MDT consideration of cancer and
patient characteristics
A quarter of MDTs (27%) stated they do not monitor
response in patients planned to undergo mastectomy.
Where response to NACT is monitored, results are rou-
tinely discussed in MDT meetings at 76% of centres with
22% of centres discussing selected patients only, and 2%
(one centre) foregoing MDT discussion completely.
When using NET, 75% of MDTs site a marker clip;
86% of these centres deploy the clip prior to treatment,
with 7% siting it during treatment and 7% varying the
timing in response to practicalities. The median reported
duration of NET was 6 months (range 3–9months)
before proceeding to surgery. All centres using NET
monitor response clinically, with 95% also using radio-
logical modalities (Fig. 3). Patients on NET are routinely
discussed in 60% of MDTs, selectively discussed in 30%
of MDTs and not discussed in 10% of MDTs.
Post NST loco-regional treatment
When managing the breast post NST 74% of centres
practise response-adapted surgery whereas 26% stated
that they resect the original tumour footprint, regardless
of the extent of clinical or radiological response to treat-
ment. The majority of centres carry out post-NST senti-
nel lymph node biopsy (SLNB) in patients with clinically
negative axillae at diagnosis (73% post-NACT and 84%
post-NET). In patients with clinically positive axillary
nodes at diagnosis 60% of centres stated that they would
carry out axillary node clearance (ANC) regardless of re-
sponse to NACT, and 69% (n=25) following NET. Thir-
teen percent of MDTs would re-assess the axilla
following NACT and 25% following NET prior to mak-
ing a surgical decision.
Post-NST, virtually all units stated that they would tre-
ate the conserved breast with adjuvant radiotherapy
(97%). Post-mastectomy radiotherapy (PMRT) was
largely driven by pre-treatment tumour size and nodal
status, with 92% of MDTs stating that they give PMRT
where pre-treatment tumour size was ≥50 mm, and 87%
giving supraclavicular fossa (SCF) radiotherapy based on
a pre-treatment diagnosis of N2 disease.
Thirty six percent of units that perform SLNB prior to
NST would proceed to an ANC post-treatment, without
further assessing the axilla if sentinel nodes are positive.
Patients found to have a positive axilla on post-NST
Fig. 3 Prefered modalities used in the monitoring of neoadjuvant systemic therapy response. Represented as percentage of MDTs using each
modality for Fig. 3 a: neoadjuvant chemotherapy and Fig. 3 b neoadjuvant endocrine therapy. As some units use more than one imaging
modality, percentages may add up to > 100%
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SLNB are managed on an individualised basis at 31%
(n=11) of centres following NACT and 54% (n=19) of
centres following NET. Approximately half of MDTs
would perform a completion ANC; 54% (n=19) following
NACT, and 46% (n=16) for NET.
Histopathology
In 86% of MDTs, a reporting system is routinely used to
describe the extent of pathological response to NACT.
Figure 4 summarises the reporting systems used, with 2
centres not responding to this question (5%). Ki67 is
routinely measured in post-NST specimens in only 11%
of centres, with 8% reporting it in selected circumstances
such as clinical trials, and 5% not responding. In con-
trast, only 46% of MDTs use a system to report response
to NET, and 14 centres use a descriptive report only.
Discussion
This study gives an overview of the stated practice in the
use of neoadjuvant systemic therapy for breast cancer in
the UK, confirming that wide variation in such practice
exists. All 39 participating centres in the first phase of
the NeST Study offer NACT, although it appears that a
relatively small proportion of patients (median 10%,
range 5–60%) are recommended this treatment strategy.
There is wide variation reported in the frequency with
which NACT is recommended in UK MDTs, although
we showed no difference in stated rates of use between
teaching hospitals and DGHs, albeit in a relatively small
number of hospitals using self-reported data. When con-
sidering the findings of studies such as MasDA, and con-
sidering the potential benefits for patients of using NST
(both in terms of surgical downstaging and the utility of
treatment response as a prognostic biomarker), it is
likely that there is under-utilisation of this approach
across the UK [15]. Furthermore, the variation in usage
of NACT between MDTs appears too wide to be
accounted for by variation in patient populations be-
tween units, although it is known that the age structure
of the UK population varies by local area, and that use
of both NACT and NET may consequently vary with
age [21]. Individual patient-level data for patients being
treated with NeST was not collected in the National
Practice Questionnaire; however, the prospective audit
phase of NeST will seek to explore this aspect of neoad-
juvant therapy usage in more detail [18].
It remains clear that surgical downstaging is a primary in-
dication for the use of NACT in many MDTs. However, it
is equally clear that other indications for recommending
NACT are emerging, in line with disease biology. Response
to treatment has been shown to be a valuable predictor of
long-term outcome following neoadjuvant chemotherapy
[22]. However, it is also increasingly clear that pathological
response to treatment can be utilised as a functional bio-
marker, to guide the use of subsequent adjuvant therapies
where patients have an incomplete response to treatment,
particularly in the context of certain disease subtypes, such
as HER2+ or triple negative disease [5, 6].
Around two thirds of MDTs in this survey are using NET.
However, this approach tends to be offered only to a small
proportion of patients (a median of 4% in this study), and
appears to be primarily used in the UK where disease is con-
sidered to be locally advanced or inoperable, to facilitate sur-
gical treatment, with a relatively small proportion of centres
employing this approach to downstage disease to reduce the
extent of surgery. Similarly low usage of NET was seen in
Fig. 4 Histopathology reporting systems post neoadjuvant chemotherapy
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the MasDA study, although many post-menopausal
women with ER-positive breast cancer were recom-
mended mastectomy due to a large tumour to breast size
ratio, and could potentially have benefitted from NET
[15]. A 2016 metanalysis suggests that NET with aroma-
tase inhibitors is comparable to NACT in terms of radio-
logical and clinical response rates, with similar rates of
breast conserving surgery, [11]. In this meta-analysis it is
noted that 90% of published studies of NET include post-
menopausal women, and that there is little data on the
use of NET in pre-menopausal women with hormone re-
ceptor positive breast cancer. Clearly the role and benefits
of NET in such pre-menopausal women is yet to be estab-
lished, and the prospective audit phase of NET will deter-
mine the age distribution and menopausal status of
women in the UK being treatment with NET [18]. How-
ever, this data, taken together with the MasDA findings
show that there remains a clear reluctance to utilise this
approach routinely in clinical practice within the UK des-
pite the low pCR reported with NACT in this group. The
reasons for this remain unclear, but may relate to a per-
ceived lack of evidence regarding the long-term onco-
logical outcomes of this approach. While genomic assays
may be of value here and increase clinician confidence in
decision-making, there remains a need for further high-
quality clinical trial data to guide the management of this
patient group.
It is also clear from this data that there is a wide vari-
ation in radiological monitoring and pathological report-
ing during and after neoadjuvant therapy, with no
consensus on the optimal radiological method of moni-
toring response. With respect to pathological reporting,
several reporting systems are available, and current UK
pathology guidelines do not recommend a particular sys-
tem [23]. Although the Residual Cancer Burden system
is increasingly regarded as the gold standard for report-
ing pathological response following neoadjuvant chemo-
therapy and is the system recommended for neoadjuvant
trials, only around one quarter of units are using this
reporting system routinely, with around 20% of units is-
suing descriptive reports only [24].
Although surgical downstaging was noted to be a key in-
dication for recommending NAC in this study, around 25%
of centres stated that following treatment, the surgical goal
remained removal of the original tumour footprint, regard-
less of response. This is in contrast to the St Gallen consen-
sus guidance, which recommended that excision of the
initial tumour bed was not required [25]. It seems likely,
therefore, that the opportunity to de-escalate breast surgery
following NACT is not being fully utilised in some patients.
Management of the axilla following NACT has been a
controversial area, although subsequent to this survey, UK
multidisciplinary recommendations have been produced to
guide treatment [26]. At the time of this study, the majority
of patients diagnosed with clinically node negative breast
cancer receiving NACT were undergoing post-treatment
SLNB. However, in patients presenting with node-positive
disease, the majority of centres were performing axillary
node clearance, with only a small number of centres carry-
ing out axillary reassessment and response-guided treat-
ment of the axilla. It appears likely, therefore, that a
proportion of patients may not have the opportunity for
de-escalation of axillary surgery following NACT, although
the impact of the published guidance remains to be seen.
Clearly, there are some limitations to the data pro-
vided by this questionnaire. Only 39 of 144 breast units
(27%) in the UK participated in the study, and conse-
quently there may be selection bias as these units may
not be representative of UK practice more broadly. Al-
though this data has been supplied by all members of
the MDT and therefore should represent an accurate re-
flection of multidisciplinary perspectives, we accept that
this study is based on reported rather than actual prac-
tice of MDTs. We note that the self-reported range of
NACT use is from 5 to 60%, with the upper limit
appearing surpriginly high. While this may reflect genu-
ine variation in NACT use (and that some centres, in-
cluding specialist tertiary referral centres are high users
of this treatment approach), it is possible that self-
reported data may not be entirely reflective of actual
patterns of care. Consequently the data may be reflective
of perceived rather than actual practice, as studies (albeit
in other specialties) have demonstrated there to be a dif-
ference between these [27]. Furthermore, units were not
specifically asked about compliance with national and
international guidelines regarding the use of NeST such
as UK NICE guidance or the St Gallen guidelines [7, 8].
However, the prospective audit phase of the NeST study
will provide valuable insight into decision-making on an
individual patient basis across UK MDTs [18].
In spite of these limitations, to our knowledge this is the
first UK study to broadly examine real-world stated practice
in terms of the use of neoadjuvant systemic therapy. It is
clear that there is wide variety in perceived indications for
and use of neoadjuvant systemic therapy in the UK, as well
as a lack of consensus on the optimal methods for monitor-
ing and reporting response and on the surgical management
of the primary tumour following systemic therapy. Although
NICE guidance outlines potential indications of the use of
NST in breast cancer, this study indicates a clear need for
both further research and the development of multidisciplin-
ary guidance with respect to monitoring of response, patho-
logical reporting and surgical decision-making, to ensure
optimal outcomes for breast cancer patients treated with
neoadjuvant therapies. We await the prospective phase of
the NeST study, which will allow the corroboration of these
results with the real-world use of neoadjuvant systemic ther-
apy for breast cancer in the UK [18].
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